Opendata, web and dolomites

VIRION SIGNED

Viruses, Immune stimulation and RNA Interference in Oncology Network

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VIRION project word cloud

Explore the words cloud of the VIRION project. It provides you a very rough idea of what is the project "VIRION" about.

superior    antitumor    oncology    lytic    cells    therapeutic    tool    potentiate    rna    competitive    tumors    genes    micro    treatment    ally    adoptive    trials    had    elimination    infiltration    hurdle    act    therapy    lymphocytic    cancer    destroy    sirna    radiation    immune    efficacy    astonishing    combining    favorable    shown    combination    checkpoints    techniques    viruses    infused    variety    suppression    modulating    patient    fight    virion    interference    stimulation    back    ed    network    lymphocytes    vivo    chemotherapy    environment    cancers    successes    powerful    prognostic    ex    internationally    models    direct    regime    inflammation    suppressive    lines    genetically    patients    oncolytic    adenoviruses    therapies    relieve    outcomes    first    modified    clinical    immunotherapy    limits    expanded    microenvironment    anti    play    stimulated    cell    enhanced    virotherapy    proven    tumor    reaction    surgery    regimens    subsequent   

Project "VIRION" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.virion-consortium.eu
 Total cost 1˙304˙413 €
 EC max contribution 1˙304˙413 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-EID
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 510˙748.00
2    TILT BIOTHERAPEUTICS OY FI (HELSINKI) participant 538˙290.00
3    ORCA Therapeutics BV NL (Nijmegen) participant 255˙374.00
4    STICHTING VU NL (AMSTERDAM) participant 0.00
5    Adiutide Pharmaceuticals GmbH DE (Glashuetten) partner 0.00
6    Diamond Biopharm Limited UK (Sawbridgeworth) partner 0.00
7    Hyphen Projects BV NL (Hilversum) partner 0.00
8    Netherlands society of gene and cell therapy NL (Amsterdam) partner 0.00
9    Quintess Consultancy BV NL (Schiedam) partner 0.00

Map

 Project objective

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques.

Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses.

However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

 Deliverables

List of deliverables.
Doctorate Other 2020-01-14 16:23:20
Presentation Other 2019-10-15 13:18:34
Supervisory board of the network Other 2019-06-12 11:55:37
Recruitment Other 2019-06-12 11:55:37
Public website Websites, patent fillings, videos etc. 2019-06-12 11:55:37
Communication Websites, patent fillings, videos etc. 2019-06-12 11:55:37

Take a look to the deliverables list in detail:  detailed list of VIRION deliverables.

 Publications

year authors and title journal last update
List of publications.
2016 Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri Tähtinen, Víctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus Vähä-Koskela, Anna Kanerva, Akseli Hemminki
Corrigendum to “Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma”
published pages: 2033, ISSN: 1525-0016, DOI: 10.1038/mt.2016.196
Molecular Therapy 24/11 2019-10-29
2018 Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero, Dave Lumen, Mikko Siurala, Anu J. Airaksinen, Victor Cervera-Carrascon, Siri Tähtinen, Anna Kanerva, Akseli Hemminki
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
published pages: 109-121, ISSN: 2372-7705, DOI: 10.1016/j.omto.2018.10.005
Molecular Therapy - Oncolytics 11 2019-10-29
2018 Tereza Brachtlova, Victor van Beusechem
Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens
published pages: 228, ISSN: 2073-4409, DOI: 10.3390/cells7120228
Cells 7/12 2019-10-29
2019 Camilla Heiniö, Suvi Sorsa, Mikko Siurala, Susanna Grönberg-Vähä-Koskela, Riikka Havunen, Elina Haavisto, Anniina Koski, Otto Hemminki, Sadia Zafar, Víctor Cervera-Carrascon, Eleonora Munaro, Anna Kanerva, Akseli Hemminki
Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs
published pages: 740-752, ISSN: 1043-0342, DOI: 10.1089/hum.2018.240
Human Gene Therapy 30/6 2019-10-29
2016 Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri Tähtinen, Víctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus Vähä-Koskela, Anna Kanerva, Akseli Hemminki
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
published pages: 1435-1443, ISSN: 1525-0016, DOI: 10.1038/mt.2016.137
Molecular Therapy 24/8 2019-10-29
2019 Victor Cervera-Carrascon, Riikka Havunen, Akseli Hemminki
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
published pages: 443-455, ISSN: 1471-2598, DOI: 10.1080/14712598.2019.1595582
Expert Opinion on Biological Therapy 19/5 2019-10-29
2017 Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna Grönberg-Vähä-Koskela, Michael Behr, Siri Tähtinen, João Manuel Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva, Akseli Hemminki
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
published pages: 77-86, ISSN: 2372-7705, DOI: 10.1016/j.omto.2016.12.004
Molecular Therapy - Oncolytics 4 2019-10-29
2018 Sadia Zafar, Suvi Sorsa, Mikko Siurala, Otto Hemminki, Riikka Havunen, Victor Cervera-Carrascon, João Manuel Santos, Hongjie Wang, Andre Lieber, Tanja De Gruijl, Anna Kanerva, Akseli Hemminki
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
published pages: e1490856, ISSN: 2162-402X, DOI: 10.1080/2162402x.2018.1490856
OncoImmunology 7/10 2019-10-29
2018 João Manuel Santos, Víctor Cervera-Carrascon, Riikka Havunen, Sadia Zafar, Mikko Siurala, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy
published pages: 2243-2254, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.06.001
Molecular Therapy 26/9 2019-10-29
2017 Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma
published pages: e1319028, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1319028
OncoImmunology 6/9 2019-10-29
2018 V. Cervera-Carrascon, M. Siurala, J. M. Santos, R. Havunen, S. Tähtinen, P. Karell, S. Sorsa, A. Kanerva, A. Hemminki
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
published pages: e1412902, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1412902
OncoImmunology 7/5 2019-10-29
2017 Joao Manuel Santos, Riikka Havunen, Mikko Siurala, Víctor Cervera-Carrascon, Siri Tähtinen, Suvi Sorsa, Marjukka Anttila, Pauliina Karell, Anna Kanerva, Akseli Hemminki
Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy
published pages: 1458-1468, ISSN: 0020-7136, DOI: 10.1002/ijc.30839
International Journal of Cancer 141/7 2019-06-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIRION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIRION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

i-CONN (2019)

Interdisciplinary connectivity: Understanding and managing complex systems using connectivity science

Read More  

NanoCarb (2018)

Glyco-Nanoparticles for Applications in Advance Nanomedicine

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More